RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustionJanuary 31, 2024 - Novartis’ anti-TIM-3 antibody has flunked a phase 3 blood cancer trial, failing to prevent T-cell exhaustion, as one significant deficiency.
https://www.fiercebiotech.com/biotech/novartis-calls-time-tim-3-axing-cancer-candidate-after-phase-3-flop